We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

J&J Can't Ax Pfizer Antitrust Suit Over Remicade Biosimilar

Law360 (August 10, 2018, 8:29 PM EDT) -- Pfizer Inc. has credibly shown that Johnson & Johnson may have flouted antitrust laws by coercing health insurers into not covering biosimilar versions of biologic Remicade, a Pennsylvania federal judge said in a ruling released Friday.

The ruling from U.S. District Judge J. Curtis Joyner rejected J&J’s bid to sink litigation that Pfizer launched in 2017. Judge Joyner found that Pfizer’s suit plausibly alleges that J&J breached the Sherman Act and the Clayton Act by threatening to deny rebates for Remicade if health insurers covered rival biosimilar...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.